Aetna modified CPB 0579 for microvolt T-wave alternans testing, effective September 26, 2025. Here's what billing teams need to know.
Aetna, a CVS Health company, updated its T-wave alternans coverage policy under CPB 0579 in the Aetna system. The core change affects CPT 93025 — the code for microvolt T-wave alternans (MTWA) testing using the spectral analytic method. If your cardiology or electrophysiology practice bills Aetna for sudden cardiac death risk evaluation, this policy defines exactly when CPT 93025 gets paid and when it doesn't.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | T-Wave Alternans — CPB 0579 |
| Policy Code | CPB 0579 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | Medium |
| Specialties Affected | Cardiology, Electrophysiology, Cardiac Electrophysiology |
| Key Action | Confirm ICD to support ICD placement criteria before billing CPT 93025 |
Aetna T-Wave Alternans Coverage Criteria and Medical Necessity Requirements 2025
Aetna's coverage policy under CPB 0579 is narrow and specific. CPT 93025 — microvolt T-wave alternans for assessment of ventricular arrhythmias — is medically necessary for one defined use case: evaluating patients at risk of sudden cardiac death who already meet criteria for implantable cardioverter-defibrillator (ICD) placement.
That's the gating requirement. The patient must meet ICD placement criteria first. MTWA testing isn't a stand-alone screening tool under this policy — it's a confirmatory step in a patient already headed toward an ICD evaluation.
The spectral analytic method is the only covered technique. Other methods of T-wave alternans measurement don't qualify under this coverage policy. If your ordering physician is using a different analytic approach, the claim will deny.
Medical necessity documentation needs to connect two things clearly: the patient's risk of sudden cardiac death and the clinical basis for ICD candidacy. If your clinical notes don't establish both, you're building a denial before you even submit.
There's no mention of prior authorization requirements in the published CPB 0579 policy summary. That said, Aetna plan documents vary. Check the member's specific plan before assuming prior auth isn't needed — some commercial plans layer additional requirements on top of CPB criteria.
Aetna T-Wave Alternans Exclusions and Non-Covered Indications
The policy is direct on this: MTWA testing is not covered for the diagnosis of arrhythmias. That language appears directly in the CPT 93025 code description in the policy.
This distinction matters more than it looks. A patient who presents with palpitations or documented arrhythmia — but who hasn't been evaluated for ICD placement — doesn't meet the coverage threshold. Billing CPT 93025 in that scenario is a claim denial waiting to happen.
The real issue here is documentation. The clinical note needs to frame the MTWA test as part of an ICD candidacy workup, not as a diagnostic workup for arrhythmia. Same test, very different framing — and Aetna pays attention to the distinction.
MTWA testing ordered as a screening tool — without a documented clinical pathway toward ICD evaluation — also falls outside this coverage policy. Aetna won't pay for it under CPB 0579 in that context.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| MTWA testing (spectral analytic method) for sudden cardiac death risk in ICD-eligible patients | Covered | CPT 93025 | Patient must meet ICD placement criteria; spectral analytic method only |
| MTWA testing for diagnosis of arrhythmias | Not Covered | CPT 93025 | Explicitly excluded in CPB 0579 |
| MTWA testing as stand-alone cardiac screening | Not Covered | CPT 93025 | No documented ICD candidacy = no coverage |
| MTWA testing using non-spectral analytic methods | Not Covered | CPT 93025 | Policy specifies spectral analytic method only |
Aetna T-Wave Alternans Billing Guidelines and Action Items 2025
The September 26, 2025 effective date has passed. If you're billing CPT 93025 for Aetna members now, these are the steps to get clean claims through.
| # | Action Item |
|---|---|
| 1 | Audit your CPT 93025 claims from September 26, 2025 forward. Pull every claim with CPT 93025 billed to Aetna and confirm the clinical documentation supports ICD candidacy — not just arrhythmia diagnosis or general cardiac risk. |
| 2 | Update your charge capture workflow for CPT 93025. Add a hard stop or checklist item that requires the ordering provider to document ICD candidacy before the test is ordered. This prevents the wrong indication from reaching the claim in the first place. |
| 3 | Verify the analytic method in the test report. The spectral analytic method is the only covered approach under CPB 0579. If your testing vendor or ordering physician uses a different MTWA method, flag those claims before submission. Reimbursement depends on method, not just the code. |
| 4 | Review your ICD-10 pairing for CPT 93025. The ICD-10 codes attached to MTWA claims need to support sudden cardiac death risk and ICD evaluation — not arrhythmia diagnosis. We've listed the relevant diagnosis codes below. Pull your current claim templates and check what's defaulting in. |
| 5 | Check plan-level prior auth requirements. CPB 0579 doesn't mandate prior authorization, but individual Aetna plan documents can. For high-cost patients or complex cases, verify the member's plan before the test is performed — not after. |
| 6 | Brief your cardiology and EP ordering physicians. They need to understand that MTWA ordered for arrhythmia diagnosis won't pay under this policy. The clinical framing in their notes has to match Aetna's coverage criteria. This isn't just a billing issue — it starts with the order. |
| 7 | Flag T-wave alternans billing in your denial tracking system. If you're seeing CPT 93025 denials, categorize them by reason code. Denials tied to "not medically necessary" or "non-covered indication" under CPB 0579 need a different appeal strategy than administrative denials. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for T-Wave Alternans Under CPB 0579
Covered CPT Code (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 93025 | CPT | Microvolt T-wave alternans for assessment of ventricular arrhythmias — not covered for arrhythmia diagnosis; covered for ICD candidacy evaluation using spectral analytic method |
Key ICD-10-CM Diagnosis Codes
The policy lists 117 ICD-10-CM codes. The published data includes B57.0 (Chagas' disease) as a documented example. The full code set spans conditions associated with sudden cardiac death risk and ICD candidacy — including cardiomyopathies, arrhythmias, and structural heart disease. Pull the full ICD-10 list from the CPB 0579 policy document directly to build your claim templates. Using a diagnosis code outside the covered list is one of the fastest ways to generate a medical necessity denial on CPT 93025 claims.
| Code | Description |
|---|---|
| B57.0 | Chagas' disease |
| See full policy for remaining 116 ICD-10-CM codes | Available at CPB 0579 on PayerPolicy |
Get the Full Picture for CPT 93025
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.